New Classifications of Five Distinct “Sleep” Profi... ...
A Professional Overview of Hypertension ...
High-speed imaging tracks live brain cell activity...
Drug candidate slows motor neuron disease progress...
Drug candidate slows motor neuron disease progress...
Mark Cuban: A Master Disrupter for American Health...
Superbugs on your plate: How antimicrobial resistance spread...
June 13,2026
Can marijuana cause lung cancer?...
June 12,2026
Standard depression screening could be missing key symptoms ...
June 11,2026
More women are having babies later in life. How to improve y...
June 10,2026
For severe babesiosis, red blood cell exchange is associated...
June 09,2026
Cause or effect? Study answers question about gene linked wi...
June 08,2026
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
Eye Infections (Updated) | Clinical Medicine...
Announcement of the 2025 Nobel Prize in ...
Dr. Fauci among hundreds who've contract...
Why are young, healthy adults experienci...
Reprogramming Stem Cells Could Cure Type...
More News
Taletrectinib Under NMPA Review in China for Advanced or Metastatic ROS1+ NSCLC

Taletrectinib Under NMPA Review in China for Advanced or Metastatic ROS1+ NSCLC

November 22, 2023Courtney FlahertyThe Center for Drug Evaluation of China’s National Medical Products Administration has accepted the new drug application seeking the approval of the next-generation R
World medicine November 23,2023
Taletrectinib Under NMPA Review in China for Advanced or Metastatic ROS1+ NSCLC

Taletrectinib Under NMPA Review in China for Advanced or Metastatic ROS1+ NSCLC

November 22, 2023Courtney FlahertyThe Center for Drug Evaluation of China’s National Medical Products Administration has accepted the new drug application seeking the approval of the next-generation R
World medicine November 23,2023
HIPEC: A promising treatment for certain patients with Stage IV abdominal cancer

HIPEC: A promising treatment for certain patients with Stage IV abdominal cancer

A technique that delivers high doses of heated chemotherapy directly to the abdominal cavity is a promising treatment for certain patients with Stage IV cancer. Hyperthermic intraperitoneal chemothera
World medicine November 23,2023
HIPEC: A promising treatment for certain patients with Stage IV abdominal cancer

HIPEC: A promising treatment for certain patients with Stage IV abdominal cancer

A technique that delivers high doses of heated chemotherapy directly to the abdominal cavity is a promising treatment for certain patients with Stage IV cancer. Hyperthermic intraperitoneal chemothera
World medicine November 23,2023
Sovleplenib Elicits Durable Responses in Primary Immune Thrombocytopenia

Sovleplenib Elicits Durable Responses in Primary Immune Thrombocytopenia

August 24, 2023Kristi RosaSovleplenib provided a statistically significant and clinically meaningful increase in durable response rate over placebo in adult patients with primary immune thrombocytopen
World medicine November 23,2023
Sovleplenib Elicits Durable Responses in Primary Immune Thrombocytopenia

Sovleplenib Elicits Durable Responses in Primary Immune Thrombocytopenia

August 24, 2023Kristi RosaSovleplenib provided a statistically significant and clinically meaningful increase in durable response rate over placebo in adult patients with primary immune thrombocytopen
World medicine November 23,2023
Novel cell signaling pathway could be targeted against aggressive pancreatic cancers

Novel cell signaling pathway could be targeted against aggressive pancreatic cancers

Researchers at the Johns Hopkins Kimmel Cancer Center identified a novel cell signaling pathway that potentially could be targeted in therapy for patients with aggressive pancreatic cancers.In laborat
World medicine November 23,2023
Novel cell signaling pathway could be targeted against aggressive pancreatic cancers

Novel cell signaling pathway could be targeted against aggressive pancreatic cancers

Researchers at the Johns Hopkins Kimmel Cancer Center identified a novel cell signaling pathway that potentially could be targeted in therapy for patients with aggressive pancreatic cancers.In laborat
World medicine November 23,2023
SLS009 Plus Venetoclax/Azacitidine Displays Activity, Tolerability in Relapsed/Refractory AML

SLS009 Plus Venetoclax/Azacitidine Displays Activity, Tolerability in Relapsed/Refractory AML

October 17, 2023Chris RyanThe addition of SLS009 to the combination of venetoclax and azacitidine produced anti-leukemic effects and was safe in patients with relapsed/refractory acute myeloid leukemi
World medicine November 23,2023
SLS009 Plus Venetoclax/Azacitidine Displays Activity, Tolerability in Relapsed/Refractory AML

SLS009 Plus Venetoclax/Azacitidine Displays Activity, Tolerability in Relapsed/Refractory AML

October 17, 2023Chris RyanThe addition of SLS009 to the combination of venetoclax and azacitidine produced anti-leukemic effects and was safe in patients with relapsed/refractory acute myeloid leukemi
World medicine November 23,2023
Nonsurgical system for controlled delivery of antibiotics to treat aggressive periodontitis in adolescents

Nonsurgical system for controlled delivery of antibiotics to treat aggressive periodontitis in adolescents

Aggressive periodontitis is a severe type of gum infection that causes the destruction of ligament and bone and can lead to tooth loss in otherwise healthy individuals. Traditional treatment typically
World medicine November 23,2023
Nonsurgical system for controlled delivery of antibiotics to treat aggressive periodontitis in adolescents

Nonsurgical system for controlled delivery of antibiotics to treat aggressive periodontitis in adolescents

Aggressive periodontitis is a severe type of gum infection that causes the destruction of ligament and bone and can lead to tooth loss in otherwise healthy individuals. Traditional treatment typically
World medicine November 23,2023
SCO-101 Plus FOLFIRI Provides Survival Benefit in Metastatic Colorectal Cancer

SCO-101 Plus FOLFIRI Provides Survival Benefit in Metastatic Colorectal Cancer

November 22, 2023Kristi RosaSCO-101 in combination with leucovorin, fluorouracil, and irinotecan (FOLFIRI) provided a clinically meaningful overall survival benefit in heavily pretreated patients with
World medicine November 23,2023
SCO-101 Plus FOLFIRI Provides Survival Benefit in Metastatic Colorectal Cancer

SCO-101 Plus FOLFIRI Provides Survival Benefit in Metastatic Colorectal Cancer

November 22, 2023Kristi RosaSCO-101 in combination with leucovorin, fluorouracil, and irinotecan (FOLFIRI) provided a clinically meaningful overall survival benefit in heavily pretreated patients with
World medicine November 23,2023
Maintaining a healthy weight could reduce future gastrointestinal cancer risk

Maintaining a healthy weight could reduce future gastrointestinal cancer risk

Doctors have long stressed the importance of maintaining a healthy weight for improving overall health, but a large new study also suggests it could also reduce future gastrointestinal cancer (GI) ris
World medicine November 23,2023
Maintaining a healthy weight could reduce future gastrointestinal cancer risk

Maintaining a healthy weight could reduce future gastrointestinal cancer risk

Doctors have long stressed the importance of maintaining a healthy weight for improving overall health, but a large new study also suggests it could also reduce future gastrointestinal cancer (GI) ris
World medicine November 23,2023
RLY-4008 Shows Initial Activity With a Manageable Safety Profile in Cholangiocarcinoma

RLY-4008 Shows Initial Activity With a Manageable Safety Profile in Cholangiocarcinoma

August 31, 2023Kyle DohertyMitesh J. Borad, MD, highlights key additional findings from ReFocus and how RLY-4008 differs from currently available FGFR2 inhibitors.Mitesh J. Borad, MDThe first highly s
World medicine November 23,2023
RLY-4008 Shows Initial Activity With a Manageable Safety Profile in Cholangiocarcinoma

RLY-4008 Shows Initial Activity With a Manageable Safety Profile in Cholangiocarcinoma

August 31, 2023Kyle DohertyMitesh J. Borad, MD, highlights key additional findings from ReFocus and how RLY-4008 differs from currently available FGFR2 inhibitors.Mitesh J. Borad, MDThe first highly s
World medicine November 23,2023
Testing hundreds of existing therapeutics to fight blood cancer more effectively

Testing hundreds of existing therapeutics to fight blood cancer more effectively

Multiple myeloma is a rare blood cancer caused by the uncontrolled multiplication of abnormal plasma cells. These plasma cells are a special type of white blood cells that play an important role in th
World medicine November 23,2023
Testing hundreds of existing therapeutics to fight blood cancer more effectively

Testing hundreds of existing therapeutics to fight blood cancer more effectively

Multiple myeloma is a rare blood cancer caused by the uncontrolled multiplication of abnormal plasma cells. These plasma cells are a special type of white blood cells that play an important role in th
World medicine November 23,2023
More News
Week’s Top
Podcasts
... Preparing for a tough exam? A tough gym workout could help with your studies ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... Brain activity goes to extremes in soccer fans, neuroimaging reveals ...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com